AU2003234186B2 - Peptide inhibitors of protein kinase C Gamma for pain management - Google Patents
Peptide inhibitors of protein kinase C Gamma for pain management Download PDFInfo
- Publication number
- AU2003234186B2 AU2003234186B2 AU2003234186A AU2003234186A AU2003234186B2 AU 2003234186 B2 AU2003234186 B2 AU 2003234186B2 AU 2003234186 A AU2003234186 A AU 2003234186A AU 2003234186 A AU2003234186 A AU 2003234186A AU 2003234186 B2 AU2003234186 B2 AU 2003234186B2
- Authority
- AU
- Australia
- Prior art keywords
- peptide
- pain
- seq
- domain
- ypkc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 228
- 208000002193 Pain Diseases 0.000 title claims description 135
- 230000036407 pain Effects 0.000 title claims description 119
- 239000003112 inhibitor Substances 0.000 title description 9
- 102100037314 Protein kinase C gamma type Human genes 0.000 title 1
- 108010062154 protein kinase C gamma Proteins 0.000 title 1
- 108090000315 Protein Kinase C Proteins 0.000 claims description 55
- 238000012360 testing method Methods 0.000 claims description 51
- 102000003923 Protein Kinase C Human genes 0.000 claims description 49
- 230000000694 effects Effects 0.000 claims description 49
- 108010044467 Isoenzymes Proteins 0.000 claims description 46
- 150000001875 compounds Chemical class 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 27
- 238000007726 management method Methods 0.000 claims description 24
- 230000020341 sensory perception of pain Effects 0.000 claims description 19
- 230000027455 binding Effects 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 208000000094 Chronic Pain Diseases 0.000 claims description 12
- 238000002347 injection Methods 0.000 claims description 11
- 239000007924 injection Substances 0.000 claims description 11
- 230000003247 decreasing effect Effects 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 4
- 108091000080 Phosphotransferase Proteins 0.000 claims description 3
- 208000005298 acute pain Diseases 0.000 claims description 3
- 210000000170 cell membrane Anatomy 0.000 claims description 3
- 238000012875 competitive assay Methods 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 230000014725 late viral mRNA transcription Effects 0.000 claims description 3
- 150000002894 organic compounds Chemical class 0.000 claims description 3
- 102000020233 phosphotransferase Human genes 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 69
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 46
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 38
- 241000700159 Rattus Species 0.000 description 27
- 230000004048 modification Effects 0.000 description 21
- 238000012986 modification Methods 0.000 description 21
- 229960002504 capsaicin Drugs 0.000 description 20
- 235000017663 capsaicin Nutrition 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- 238000011282 treatment Methods 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 13
- 208000004454 Hyperalgesia Diseases 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 230000006399 behavior Effects 0.000 description 10
- 210000002683 foot Anatomy 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000005945 translocation Effects 0.000 description 10
- 102000006438 Receptors for Activated C Kinase Human genes 0.000 description 9
- 108010044157 Receptors for Activated C Kinase Proteins 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 208000035154 Hyperesthesia Diseases 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 7
- 230000000202 analgesic effect Effects 0.000 description 7
- 230000003278 mimic effect Effects 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 230000036592 analgesia Effects 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 230000001473 noxious effect Effects 0.000 description 6
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108010033276 Peptide Fragments Proteins 0.000 description 4
- 102000007079 Peptide Fragments Human genes 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 238000007913 intrathecal administration Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 210000000929 nociceptor Anatomy 0.000 description 4
- 108091008700 nociceptors Proteins 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 210000000278 spinal cord Anatomy 0.000 description 4
- 210000003594 spinal ganglia Anatomy 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 206010064012 Central pain syndrome Diseases 0.000 description 3
- 101710103106 Guanine nucleotide-binding protein subunit beta-2-like 1 Proteins 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 206010053552 allodynia Diseases 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 150000001982 diacylglycerols Chemical class 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 210000000548 hind-foot Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 208000021722 neuropathic pain Diseases 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 206010058019 Cancer Pain Diseases 0.000 description 2
- 108700006830 Drosophila Antp Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 102000042846 PKC family Human genes 0.000 description 2
- 108091082203 PKC family Proteins 0.000 description 2
- 210000003766 afferent neuron Anatomy 0.000 description 2
- 238000004873 anchoring Methods 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000003502 anti-nociceptive effect Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- LLEJIEBFSOEYIV-UHFFFAOYSA-N chelerythrine Chemical compound C1=C2OCOC2=CC2=CC=C3C4=CC=C(OC)C(OC)=C4C=[N+](C)C3=C21 LLEJIEBFSOEYIV-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000003028 elevating effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000000917 hyperalgesic effect Effects 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000009593 lumbar puncture Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000003040 nociceptive effect Effects 0.000 description 2
- 230000037324 pain perception Effects 0.000 description 2
- 230000008058 pain sensation Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 150000004633 phorbol derivatives Chemical class 0.000 description 2
- 239000002644 phorbol ester Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- HXQRGYNEDCHJPJ-UHFFFAOYSA-N 2,6-diamino-n-[(1-tridecanoylpiperidin-2-yl)methyl]hexanamide Chemical compound CCCCCCCCCCCCC(=O)N1CCCCC1CNC(=O)C(N)CCCCN HXQRGYNEDCHJPJ-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 108700031308 Antennapedia Homeodomain Proteins 0.000 description 1
- 101100181137 Caenorhabditis elegans pkc-3 gene Proteins 0.000 description 1
- 206010062746 Carditis Diseases 0.000 description 1
- 108091005462 Cation channels Proteins 0.000 description 1
- 208000029147 Collagen-vascular disease Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- RATMHCJTVBHJSU-UHFFFAOYSA-N Dihydrochelerythrine Natural products C1=C2OCOC2=CC2=C(N(C)C(O)C=3C4=CC=C(C=3OC)OC)C4=CC=C21 RATMHCJTVBHJSU-UHFFFAOYSA-N 0.000 description 1
- 101100269980 Drosophila melanogaster aPKC gene Proteins 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700043304 PKC-3 Proteins 0.000 description 1
- 101150010978 PRKCE gene Proteins 0.000 description 1
- 101150001670 PRKCG gene Proteins 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 102000011040 TRPV Cation Channels Human genes 0.000 description 1
- 108010062740 TRPV Cation Channels Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003070 anti-hyperalgesia Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000006406 biphasic response Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229930194791 calphostin Natural products 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000009956 central mechanism Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000054 fungal extract Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000021646 inflammation of heart layer Diseases 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 238000011422 pharmacological therapy Methods 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000031893 sensory processing Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2009201593A AU2009201593B2 (en) | 2002-04-22 | 2009-04-22 | Peptide inhibitors of protein kinase C y for pain management |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37453002P | 2002-04-22 | 2002-04-22 | |
| US60/374,530 | 2002-04-22 | ||
| PCT/US2003/012542 WO2003089457A2 (en) | 2002-04-22 | 2003-04-22 | Peptide inhibitors of protein kinase c ϝ for pain management |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009201593A Division AU2009201593B2 (en) | 2002-04-22 | 2009-04-22 | Peptide inhibitors of protein kinase C y for pain management |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2003234186A1 AU2003234186A1 (en) | 2003-11-03 |
| AU2003234186B2 true AU2003234186B2 (en) | 2009-01-22 |
Family
ID=29251202
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003234186A Ceased AU2003234186B2 (en) | 2002-04-22 | 2003-04-22 | Peptide inhibitors of protein kinase C Gamma for pain management |
| AU2003234185A Ceased AU2003234185C1 (en) | 2002-04-22 | 2003-04-22 | Peptide inhibitors of protein kinase C |
| AU2009201593A Ceased AU2009201593B2 (en) | 2002-04-22 | 2009-04-22 | Peptide inhibitors of protein kinase C y for pain management |
| AU2009201760A Ceased AU2009201760B2 (en) | 2002-04-22 | 2009-05-04 | Peptide inhibitors of protein kinase C |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003234185A Ceased AU2003234185C1 (en) | 2002-04-22 | 2003-04-22 | Peptide inhibitors of protein kinase C |
| AU2009201593A Ceased AU2009201593B2 (en) | 2002-04-22 | 2009-04-22 | Peptide inhibitors of protein kinase C y for pain management |
| AU2009201760A Ceased AU2009201760B2 (en) | 2002-04-22 | 2009-05-04 | Peptide inhibitors of protein kinase C |
Country Status (6)
| Country | Link |
|---|---|
| US (8) | US7459424B2 (enExample) |
| EP (3) | EP1501533A4 (enExample) |
| JP (5) | JP2005527209A (enExample) |
| AU (4) | AU2003234186B2 (enExample) |
| CA (3) | CA2482598C (enExample) |
| WO (2) | WO2003089457A2 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2482598C (en) * | 2002-04-22 | 2012-09-25 | The Board Of Trustees Of The Leland Stanford Junior University | Peptide inhibitors of protein kinase c |
| US6933275B2 (en) | 2002-05-01 | 2005-08-23 | The Board Of Trustees Of The Leland Stanford Junior University | Protein kinase C peptides for use in withdrawal |
| WO2004084889A1 (en) * | 2003-03-28 | 2004-10-07 | Pfizer Inc. | Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons |
| CA2524818A1 (en) * | 2003-05-16 | 2004-12-02 | The Board Of Trustees Of The Leland Stanford Junior University | Protein kinase c peptides for use in withdrawal |
| WO2005032575A1 (en) * | 2003-10-02 | 2005-04-14 | The Board Of Trustees Of The Leland Stanford Junior University | Protein kinase c peptides for use in withdrawal |
| US8062891B2 (en) | 2003-10-24 | 2011-11-22 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to plants |
| US8133733B2 (en) * | 2003-10-24 | 2012-03-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to target tissues |
| US20090123468A1 (en) * | 2003-10-24 | 2009-05-14 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
| JP4838722B2 (ja) | 2003-10-24 | 2011-12-14 | ゲンシア コーポレーション | ポリヌクレオチドを送達する方法、及び送達用組成物 |
| US8507277B2 (en) * | 2003-10-24 | 2013-08-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides |
| US20090208478A1 (en) * | 2003-10-24 | 2009-08-20 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
| KR20070004571A (ko) * | 2003-12-11 | 2007-01-09 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 단백질 키나제 ｃ의 동종효소-특이적 길항제 |
| US7265092B2 (en) * | 2004-09-30 | 2007-09-04 | Kai Pharmaceuticals, Inc. | Pharmaceutical formulation |
| US20060148700A1 (en) * | 2004-11-10 | 2006-07-06 | Daria Mochly-Rosen | Methods and compositions for reducing injury to a transplanted organ |
| US20060160062A1 (en) * | 2005-01-14 | 2006-07-20 | Young Lindon H | Perfusion and/or preservation solution for organs |
| EP1877424A4 (en) * | 2005-04-11 | 2010-09-29 | Pharmagap Inc | INHIBITORS OF PROTEIN KINASES AND USES THEREOF |
| WO2007016763A1 (en) * | 2005-08-05 | 2007-02-15 | Pharmagap Inc. | Peptides targeted to protein kinase c isoforms and uses thereof |
| CA2620202C (en) | 2005-08-26 | 2016-10-04 | The Board Of Trustees Of The Leland Stanford Junior University | Therapy procedure for drug delivery for trigeminal pain |
| WO2007035782A2 (en) * | 2005-09-19 | 2007-03-29 | Kai Pharmaceuticals, Inc. | Protein kinase c peptide modulators of angiogenesis |
| US20100279944A1 (en) * | 2006-03-30 | 2010-11-04 | Ronald Mathison | Suppression and treatment of neuropathic pain |
| US7741290B2 (en) * | 2006-06-01 | 2010-06-22 | The Board of Trustee of The Leland Stanford Juinior University | Method of preventing progression of hypertension-induced heart failure with PKC peptides |
| WO2008089494A2 (en) * | 2007-01-19 | 2008-07-24 | Kai Pharmaceuticals, Inc. | Methods of use of epsilon inhibitor compounds for the attenuation of pain |
| KR101775929B1 (ko) * | 2007-01-19 | 2017-09-07 | 카이 파마슈티컬즈 | 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형 |
| US20090062208A1 (en) * | 2007-02-06 | 2009-03-05 | Mochly-Rosen Daria D | Methods for maintaining blood-brain barrier integrity in hypertensive subjects using a delta-PKC inhibitor |
| MX2009010757A (es) * | 2007-04-06 | 2010-02-24 | Kai Pharmaceuticals Inc | Metodos de uso de compuestos de inhibidor gamma para atenuacion del dolor. |
| WO2008154004A2 (en) * | 2007-06-07 | 2008-12-18 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of tumor metastases using protein kinase c (pkc) inhibitors |
| WO2009085270A2 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of inhibitors of c0nnexin43 for treatment of fibrotic conditions |
| US20090318351A1 (en) * | 2008-03-12 | 2009-12-24 | Kevin Grimes | Method of treating acute st-elevation myocardial infarction with a delta pkc antagonist |
| RU2494737C2 (ru) * | 2008-03-27 | 2013-10-10 | Нестек С.А. | Способы увеличения абсорбции пептидов, пептидомиметиков и других субстратов гастроинтестинального транспортного белка |
| WO2010019965A1 (en) * | 2008-08-15 | 2010-02-18 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for modulating epsilon protein kinase c-mediated cytoprotection |
| JP6189581B2 (ja) | 2009-02-20 | 2017-08-30 | セルラー ダイナミクス インターナショナル， インコーポレイテッド | 幹細胞の分化のための方法および組成物 |
| CA2753679C (en) | 2009-02-27 | 2021-03-02 | Cellular Dynamics International, Inc. | Differentiation of pluripotent cells |
| EP2403518A4 (en) * | 2009-03-06 | 2013-01-23 | Angstrom Pharmaceuticals Inc | Compositions and methods for modulating cell migration |
| WO2010111533A2 (en) * | 2009-03-25 | 2010-09-30 | Kai Pharmaceuticals, Inc. | Transdermal delivery of pkc modulatory peptides through microporated skin |
| US20120208750A1 (en) | 2009-09-29 | 2012-08-16 | Joslin Diabetes Center, Inc. | Use of protein kinase c delta (pkcd) inhibitors to treat diabetes, obesity, and hepatic steatosis |
| CA2795698A1 (en) * | 2010-03-05 | 2011-09-09 | Angstrom Pharmaceuticals, Inc. | Modulation of intracellular signaling |
| US8785648B1 (en) | 2010-08-10 | 2014-07-22 | The Regents Of The University Of California | PKC-epsilon inhibitors |
| EP2742057B1 (en) | 2011-08-12 | 2016-04-20 | The Board of Trustees of The Leland Stanford Junior University | Compositions and methods for specific regulation of pyruvate dehydrogenase kinase |
| US9260696B2 (en) | 2012-04-24 | 2016-02-16 | Dan S. Kaufman | Method for developing natural killer cells from stem cells |
| AU2014324092B2 (en) | 2013-09-18 | 2020-02-06 | Epiaxis Therapeutics Pty Ltd | Stem cell modulation II |
| EP3180003B1 (en) | 2014-07-01 | 2022-01-12 | The Regents of the University of California | Pkc-epsilon inhibitors |
| EP3185858A4 (en) | 2014-08-25 | 2017-12-27 | University of Canberra | Compositions for modulating cancer stem cells and uses therefor |
| US11389473B2 (en) | 2015-01-07 | 2022-07-19 | Tonix Pharmaceuticals Holding Corp. | Magnesium-containing oxytocin formulations and methods of use |
| HRP20250215T1 (hr) | 2016-04-12 | 2025-06-20 | Tonix Pharma Limited | Formulacije oksitocina koje sadrže magnezij i postupci upotrebe |
| AU2018209175B2 (en) | 2017-01-17 | 2021-11-25 | Michael David FORREST | Therapeutic inhibitors of the reverse mode of ATP synthase |
| MA49564A (fr) | 2017-07-13 | 2021-04-28 | Michael David Forrest | Modulateurs thérapeutiques du mode inverse de l'atp synthase |
| AU2018363880B2 (en) | 2017-11-08 | 2022-04-07 | Epiaxis Therapeutics Pty Ltd | Immunogenic compositions and uses therefor |
| US20230003894A1 (en) * | 2019-12-16 | 2023-01-05 | Sony Semiconductor Solutions Corporation | Time-of-flight imaging circuitry, time-of-flight imaging system, time-of-flight imaging method |
| US20230104831A1 (en) * | 2020-03-31 | 2023-04-06 | Toray Industries, Inc. | An image analysis device, a control method for an image analysis device, an image analysis system, and a control method for an image analysis system |
| BR112023012422A2 (pt) | 2021-01-24 | 2023-12-12 | Michael David Forrest | Inibidores da atp sintase - usos cosmético e terapêutico |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4351829A (en) * | 1980-09-26 | 1982-09-28 | Farmitalia Carlo Erba Spa | Use of polypeptides as analgesic drugs |
| ES2123062T3 (es) | 1992-08-21 | 1999-01-01 | Biogen Inc | Polipeptidos de transporte derivados de la proteina tat. |
| US5776685A (en) * | 1993-07-19 | 1998-07-07 | Joslin Diabetes Center | Protein kinase C assay |
| US5783405A (en) * | 1994-02-01 | 1998-07-21 | Terrapin Technologies, Inc. | Rapid screening method for effectors of signal transduction |
| US5935803A (en) | 1994-02-01 | 1999-08-10 | Terrapin Technologies, Inc. | Methods to identify immunomodulators using cognate interaction of PKC-theta |
| US6165977A (en) * | 1996-10-18 | 2000-12-26 | Board Of Trustees Of The Leland Stanford Junior University | Isozyme-specific activators of protein kinase C methods and compositions |
| US6376476B1 (en) * | 1996-12-13 | 2002-04-23 | Zymogenetics Corporation | Isoprenoid pathway inhibitors for stimulating bone growth |
| US6218113B1 (en) | 1998-02-24 | 2001-04-17 | Incyte Genomics, Inc. | Human protein kinase C inhibitor |
| US6376467B1 (en) * | 1998-10-09 | 2002-04-23 | The Regents Of The University Of California | Use of inhibitors of protein kinase C epsilon to treat pain |
| EP1093379B1 (en) | 1998-07-06 | 2007-01-03 | The Regents of the University of California | Use of inhibitors of protein kinase c epsilon to treat pain |
| AU5116099A (en) * | 1998-07-21 | 2000-02-14 | Sui Xiong Cai | Novel fluorescence dyes and their applications for whole cell fluorescence screening assays for caspases, peptidases, proteases and other enzymes and the use thereof |
| GB2341389B (en) * | 1998-09-14 | 2000-07-12 | Pan Pacific Pharmaceuticals In | Useful properties of a bee venom protein and gene encoding same |
| CA2343934A1 (en) * | 1998-09-25 | 2000-04-06 | The Children's Medical Center Corporation | Short peptides which selectively modulate the activity of protein kinases |
| GB9905218D0 (en) * | 1999-03-09 | 1999-04-28 | Univ Glasgow | Neurodegenerative disorder related gene |
| JP2003516760A (ja) * | 1999-12-02 | 2003-05-20 | ユニヴァーシティー オブ ダンディー | プロテインキナーゼ調節 |
| CN1300845A (zh) | 1999-12-22 | 2001-06-27 | 上海博德基因开发有限公司 | 一种新的多肽－人二酰基甘油蛋白激酶亚单位9和编码这种多肽的多核苷酸 |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| US6496425B1 (en) * | 2000-08-21 | 2002-12-17 | Micron Technology, Inc | Multiple bit line column redundancy |
| US6855693B2 (en) * | 2001-01-18 | 2005-02-15 | The Board Of Trustees Of The Leland Stanford Junior University | Peptides for activation and inhibition of δPKC |
| CA2482598C (en) * | 2002-04-22 | 2012-09-25 | The Board Of Trustees Of The Leland Stanford Junior University | Peptide inhibitors of protein kinase c |
-
2003
- 2003-04-22 CA CA2482598A patent/CA2482598C/en not_active Expired - Fee Related
- 2003-04-22 CA CA2481512A patent/CA2481512C/en not_active Expired - Fee Related
- 2003-04-22 EP EP03728495A patent/EP1501533A4/en not_active Withdrawn
- 2003-04-22 EP EP10178878A patent/EP2332559A1/en not_active Withdrawn
- 2003-04-22 JP JP2003586177A patent/JP2005527209A/ja active Pending
- 2003-04-22 JP JP2003586176A patent/JP2005523326A/ja not_active Withdrawn
- 2003-04-22 WO PCT/US2003/012542 patent/WO2003089457A2/en not_active Ceased
- 2003-04-22 WO PCT/US2003/012541 patent/WO2003089456A2/en not_active Ceased
- 2003-04-22 US US10/421,548 patent/US7459424B2/en not_active Expired - Fee Related
- 2003-04-22 CA CA2785889A patent/CA2785889A1/en not_active Abandoned
- 2003-04-22 US US10/421,503 patent/US7507711B2/en not_active Expired - Fee Related
- 2003-04-22 AU AU2003234186A patent/AU2003234186B2/en not_active Ceased
- 2003-04-22 EP EP03728494A patent/EP1501532A4/en not_active Withdrawn
- 2003-04-22 AU AU2003234185A patent/AU2003234185C1/en not_active Ceased
- 2003-04-22 US US10/513,003 patent/US7393835B2/en not_active Expired - Fee Related
-
2007
- 2007-07-16 US US11/879,414 patent/US7833984B2/en not_active Expired - Fee Related
-
2008
- 2008-06-16 US US12/214,104 patent/US7939493B2/en not_active Expired - Fee Related
- 2008-08-27 US US12/229,992 patent/US20090143293A1/en not_active Abandoned
-
2009
- 2009-01-20 JP JP2009010402A patent/JP2009091372A/ja active Pending
- 2009-01-21 JP JP2009011456A patent/JP2009102392A/ja active Pending
- 2009-04-22 AU AU2009201593A patent/AU2009201593B2/en not_active Ceased
- 2009-05-04 AU AU2009201760A patent/AU2009201760B2/en not_active Ceased
-
2011
- 2011-05-05 US US13/101,540 patent/US8658594B2/en not_active Expired - Fee Related
-
2012
- 2012-06-06 JP JP2012128849A patent/JP2012176978A/ja active Pending
-
2014
- 2014-02-21 US US14/187,070 patent/US9365837B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003234186B2 (en) | Peptide inhibitors of protein kinase C Gamma for pain management | |
| Porreca et al. | Inhibition of neuropathic pain by selective ablation of brainstem medullary cells expressing the μ-opioid receptor | |
| Carter et al. | The yellow fluorescent protein (YFP-H) mouse reveals neuroprotection as a novel mechanism underlying chondroitinase ABC-mediated repair after spinal cord injury | |
| Xu et al. | Oral application of magnesium-l-threonate attenuates vincristine-induced allodynia and hyperalgesia by normalization of tumor necrosis factor-α/nuclear factor-κB signaling | |
| US20040067886A1 (en) | Use of inhibitors of protein kinase C epsilon to treat pain | |
| CA2336709A1 (en) | Use of inhibitors of protein kinase c epsilon to treat pain | |
| AU2012216402A1 (en) | Peptide inhibitors of protein kinase Cy for pain management | |
| Iseki et al. | Altered expression pattern of testican-1 mRNA after brain injury | |
| Harward et al. | BDNF/TrkB signaling and epileptogenesis | |
| AU2011202912A1 (en) | Peptide inhibitors of protein kinase C | |
| Sun et al. | Protein kinase C substrate activators: potential as novel antidepressants | |
| JP2010090176A (ja) | 離脱症状における使用のためのプロテインキナーゼｃペプチド |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |